Press releases and news
2026
Camurus announces expansion of Lilly collaboration
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2026/2029
Resolutions at the annual general meeting 2026 in Camurus
Camurus to present at Jefferies Global Healthcare Conference
Camurus’ Interim Report January-March 2026
Camurus Annual Report for 2025
Notice of annual general meeting 2026 in Camurus AB (publ)
Camurus receives Lund Municipality’s Business Award 2025
Change in number of shares and votes in Camurus
Change in number of shares and votes in Camurus
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Camurus’ Full Year Report 2025
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
2025
Change in number of shares and votes in Camurus
Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism
Change in number of shares and votes in Camurus
Camurus’ Nomination Committee appointed for the Annual General Meeting 2026
Camurus to present at Jefferies London Healthcare Conference
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus’ Interim Report Third Quarter 2025
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.